NUCANA PLC-ADR (NCNA)

US67022C1062 - ADR

4.1125  +0.14 (+3.59%)

Fundamental Rating

1

Taking everything into account, NCNA scores 1 out of 10 in our fundamental rating. NCNA was compared to 588 industry peers in the Biotechnology industry. Both the profitability and financial health of NCNA have multiple concerns. NCNA has a expensive valuation and it also scores bad on growth.



Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year NCNA has reported negative net income.
NCNA had a negative operating cash flow in the past year.
NCNA had negative earnings in each of the past 5 years.
In the past 5 years NCNA always reported negative operating cash flow.

1.2 Ratios

The Return On Assets of NCNA (-99.37%) is worse than 78.12% of its industry peers.
The Return On Equity of NCNA (-185.63%) is worse than 70.09% of its industry peers.
Industry RankSector Rank
ROA -99.37%
ROE -185.63%
ROIC N/A
ROA(3y)-68.86%
ROA(5y)-53.1%
ROE(3y)-110.22%
ROE(5y)-79.06%
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for NCNA so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A

More info and screens

2

2. Health

2.1 Basic Checks

The number of shares outstanding for NCNA has been increased compared to 1 year ago.
NCNA has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, NCNA has a worse debt to assets ratio.

2.2 Solvency

NCNA has a Debt/Equity ratio of 0.01. This is a healthy value indicating a solid balance between debt and equity.
The Debt to Equity ratio of NCNA (0.01) is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Altman-Z N/A
ROIC/WACCN/A
WACCN/A

2.3 Liquidity

NCNA has a Current Ratio of 1.97. This is a normal value and indicates that NCNA is financially healthy and should not expect problems in meeting its short term obligations.
NCNA's Current ratio of 1.97 is on the low side compared to the rest of the industry. NCNA is outperformed by 77.95% of its industry peers.
NCNA has a Quick Ratio of 1.97. This is a normal value and indicates that NCNA is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Quick ratio, with a value of 1.97, NCNA is doing worse than 75.90% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.97
Quick Ratio 1.97

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an nice 14.75% over the past year.
EPS 1Y (TTM)14.75%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q51.72%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Revenue growth Q2QN/A

3.2 Future

The Earnings Per Share is expected to grow by 25.97% on average over the next years. This is a very strong growth
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y20.32%
EPS Next 2Y10.09%
EPS Next 3Y5.87%
EPS Next 5Y25.97%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

NCNA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year NCNA is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y10.09%
EPS Next 3Y5.87%

More info and screens

0

5. Dividend

5.1 Amount

NCNA does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

NUCANA PLC-ADR

NASDAQ:NCNA (4/18/2024, 10:06:42 AM)

4.1125

+0.14 (+3.59%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap217.39M
Analysts
Price Target
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -99.37%
ROE -185.63%
ROCE
ROIC
ROICexc
ROICexgc
OM N/A
PM (TTM) N/A
GM N/A
FCFM
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset TurnoverN/A
Health
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio 1.97
Quick Ratio 1.97
Altman-Z
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)14.75%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y20.32%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y